Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:42:15.599Z.
Calculation as of: 2026-10-06T19:42:15.599Z.
Quote observation: 2026-10-06T19:40:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d8f500f051b8c2f6d9df2326c38ce0bcf8edb39987555b97daf7c0f1a95d0fd4
PEG RATIO
N/A
LENZ Therapeutics, Inc.
Market Cap
$118.99M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.99M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.17M | N/A |
| BGM Group Ltd. (BGM)vs › | $118.12M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.78M | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.56M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
